Wechselwirkungen · Celsentri
CELSENTRI 150 mg film-coated tablets CELSENTRI 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-118470 · Präparat HOS-094825
12 Ribavirin Ribavirin has not been studied, no CELSENTRI 300 mg interaction is expected. twice daily and ribavirin can be co-administered without dose adjustment. DRUG ABUSE Methadone Not studied, no interaction expected. CELSENTRI 300 mg twice daily and methadone can be co-administered without dose adjustment. Buprenorphine Not studied, no interaction expected. CELSENTRI 300 mg twice daily and buprenorphine can be co-administered without dose adjustment. LIPID LOWERING MEDICINAL PRODUCTS Statins Not studied, no interaction expected. CELSENTRI 300 mg twice daily and statins can be co-administered without dose adjustment. ANTIARRHYTHMICS Digoxin 0.25 mg Digoxin. AUCt: ↔ 1.00 CELSENTRI 300 mg Single Dose Digoxin. Cmax: ↔ 1.04 twice daily and digoxin (maraviroc 300 mg BID) Maraviroc concentrations not can be co-administered measured, no interaction expected. without dose adjustment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) digoxin (HOS-086172) buprenorphine (HOS-086193) ribavirin (HOS-088127)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage dd6dce3feb2afd760e4eee50e20a1853379b62d1bfd9f2390a3a8dae1d106eb6 · Zeichen 20634–22602 im Abschnitt